171 related articles for article (PubMed ID: 29020430)
1. Acute Exudative Polymorphous Paraneoplastic Vitelliform Maculopathy Managed With Intravitreal Aflibercept.
Gündüz K; Çöndü G; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2017 Oct; 48(10):844-850. PubMed ID: 29020430
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
4. Multimodal Imaging Features in Acute Exudative Paraneoplastic Polymorphous Vitelliform Maculopathy.
Li DQ; Golding J; Glittenberg C; Choudhry N
Ophthalmic Surg Lasers Imaging Retina; 2016 Dec; 47(12):1143-1146. PubMed ID: 27977838
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept.
Calvo CM; Sridhar J; Shahlaee A; Ho AC
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):474-6. PubMed ID: 27183553
[TBL] [Abstract][Full Text] [Related]
6. Acute exudative paraneoplastic polymorphous vitelliform maculopathy in five cases.
Al-Dahmash SA; Shields CL; Bianciotto CG; Witkin AJ; Witkin SR; Shields JA
Ophthalmic Surg Lasers Imaging; 2012; 43(5):366-73. PubMed ID: 22822903
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
Shah CP; Heier JS
Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
[TBL] [Abstract][Full Text] [Related]
8. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
[TBL] [Abstract][Full Text] [Related]
9. Significant Bilateral Response in Diabetic Macular Edema After Single Unilateral Intravitreal Aflibercept Injection.
Rahimy E; Nyong'o O; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2017 Feb; 48(2):167-169. PubMed ID: 28195620
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal dexamethasone implant for acute exudative polymorphous vitelliform maculopathy.
Scupola A; Abed E; Sammarco MG; Traina S; Villano A; Grimaldi G; Blasi MA
Eur J Ophthalmol; 2014; 24(5):803-7. PubMed ID: 24803155
[TBL] [Abstract][Full Text] [Related]
11. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
12. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
13. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
14. Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy.
Kovach JL; Hess H; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):593-5. PubMed ID: 27327292
[TBL] [Abstract][Full Text] [Related]
15. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
Mansour AM; Dedhia C; Chhablani J
Br J Ophthalmol; 2017 Feb; 101(2):166-169. PubMed ID: 27190127
[TBL] [Abstract][Full Text] [Related]
16. ACUTE EXUDATIVE PARANEOPLASTIC POLYMORPHOUS VITELLIFORM MACULOPATHY DURING VEMURAFENIB AND PEMBROLIZUMAB TREATMENT FOR METASTATIC MELANOMA.
Sandhu HS; Kolomeyer AM; Lau MK; Shields CL; Schuchter LM; Nichols CW; Aleman TS
Retin Cases Brief Rep; 2019 Spring; 13(2):103-107. PubMed ID: 28614138
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic cloudy vitelliform submaculopathy in primary vitreoretinal lymphoma.
Pang CE; Shields CL; Jumper JM; Yannuzzi LA
Am J Ophthalmol; 2014 Dec; 158(6):1253-1261.e2. PubMed ID: 25174893
[TBL] [Abstract][Full Text] [Related]
18. A case of recurring acute exudative polymorphous vitelliform maculopathy successfully treated with intravitreal Ozurdex injection.
Lodhia V; Robson AG; Khoda S; Lee H; Hughes E
Eur J Ophthalmol; 2024 Jan; 34(1):NP90-NP95. PubMed ID: 37350018
[TBL] [Abstract][Full Text] [Related]
19. Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report.
Lambert I; Fasolino G; Awada G; Kuijpers R; Ten Tusscher M; Neyns B
BMC Ophthalmol; 2021 Jun; 21(1):250. PubMed ID: 34090381
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
